2481-53-0

Basic information

• Product Name: 3-buten-2-one, 4-(3-fluorophenyl)-
• Synonyms: 4-(3-Fluorophenyl)but-3-en-2-one
• CAS NO: 2481-53-0
• Molecular Formula: C₁₀H₉FO
• Molecular Weight: 164.1763
• Mol File: 2481-53-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 259.929°C at 760 mmHg
• Flash Point: 104.41°C
• Density: 1.107g/cm³
• Vapor Pressure: 0.013mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: 3-buten-2-one, 4-(3-fluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-buten-2-one, 4-(3-fluorophenyl)-(2481-53-0)
• EPA Substance Registry System: 3-buten-2-one, 4-(3-fluorophenyl)-(2481-53-0)

Safety Data

• Hazardous Substances Data: 2481-53-0(Hazardous Substances Data)

Upstream product

• 67-64-1 acetone 
• 456-48-4 3-Fluorobenzaldehyde 

Downstream Products

• 1258422-85-3 (1S,6R)-1'-benzyl-6-(3-fluorophenyl)-2-methylspiro[cyclohex[2]ene-1,3'-indoline]-2',4-dione 
• 1258422-97-7 (1S,6R)-6-(3-fluorophenyl)-1',2-dimethylspiro[cyclohex[2]ene-1,3'-indoline]-2',4-dione 
• 3506-77-2 4-(3-fluorophenyl)-butan-2-one 

Relevant articles and documents

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation

Androgen receptor (AR) signaling functions as a core driving force for the progression of prostate cancer (PCa), and AR has been proved to be an effective therapeutic target even for castration-resistant prostate cancer (CRPC). Herein, structural modification via a fragments splicing strategy was performed based on two lead compounds T3 and 10e, leading to the discovery of a series of 5-methyl-1H-pyrazole derivatives. AR reporter gene assay revealed compounds A13 and A14 as potent AR antagonists. Some of the compounds in this series inhibited growth of PCa LNCaP cells more efficiently than enzalutamide. A13 and A14 also showed improved metabolic stability compared with 10e in human liver microsomes.

QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS

Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.